IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy in Adults With Brain Metastases

Part of paid clinical trials in Gainesville, Florida.

Sponsor
University of Florida
Study ID
NCT07569263
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Brain Metastases

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells — BIOLOGICAL
    Single dose of 8R-70CAR T cells administered IV

Study Details

This is a Phase I Study evaluating the safety and feasibility of IL-8 receptor-modified patient-derived activated CD70 CAR T cells in adult patients with brain metastases from primary cancer, with either newly diagnosed lesions or recurrent or progressive disease after prior therapy.

Key Dates

Start date
Jul 31, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2044

Study Design

Enrollment
12 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: IL-8 receptor-modified patient-derived activated CD70 CAR T cells
    Two dose levels Cohort 1 will receive 1 x 10\^7 cells/kg; Cohort 2 will receive 1 x 10\^8 cells/kg

Primary Outcome Measure

Number and percentage of participants with dose-limiting toxicities after receiving 8R-70CAR T-cell therapy [ Time Frame: 28 days post-infusion ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UF HealthGainesvilleFlorida32610
Taryn King, RN
[email protected]
352-273-9000

Find similar trials in Gainesville, FL

By research site
UF Health· Gainesville, FL

Related Studies